C4 Therapeutics, Inc.(CCCC)

$4.10—

Chart

C4 Therapeutics, Inc.(CCCC)

NASDAQ

$4.10—

Chart Studio

CCCC(CCCC)

CCCC

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.21

Nov 5, 2026 · Reports before open

Revenue Estimate

$5M

FY2029E EPS$0.73

FY2030E EPS$5.33

Analyst Sentiment

Wall St. Consensus

Buy

14 analysts·Moderate coverage

Score

10 Buy (71%)3 Hold (21%)1 Sell (8%)

Rating Breakdown

Strong Buy

00%

Buy

1071%

Hold

321%

Sell

17%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$7.00

+70.7%

Consensus

$7.00

+70.7%

Bull

$7.00

+70.7%

12-Month Target Range14 analysts

$7.00$7.00$7.00

Current $4.10Consensus

Current Price

$4.10

Upside to Consensus

$2.90

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-3.51%

EPS—

FY2028

Rev-13.33%

EPS—

FY2029

Rev+4249.65%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$21M	$21M	$18M	$778M	$2.62B
Low	$17M	$16M	$18M	$604M	$2.03B
High	$27M	$26M	$18M	$967M	$3.25B
EBITDA Avg	$-21M	$-21M	$-18M	$-778M	$-2.62B
Low	$-27M	$-26M	$-18M	$-967M	$-3.25B
High	$-17M	$-16M	$-18M	$-604M	$-2.03B
EBIT Avg	$-21M	$-21M	$-18M	$-778M	$-2.62B
Low	$-27M	$-26M	$-18M	$-967M	$-3.25B
High	$-17M	$-16M	$-18M	$-604M	$-2.03B
Net Income Avg	$-71M	$-76M	$-110M	$61M	$442M
Low	$-75M	$-83M	$-145M	$43M	$314M
High	$-67M	$-70M	$-75M	$80M	$582M
EPS Avg	$-0.86	$-0.92	$-1.24	$0.73	$5.33
Low	$-0.91	$-1.00	$-1.75	$0.52	$3.79
High	$-0.81	$-0.84	$-0.91	$0.97	$7.02
Analysts (Rev / EPS)	3 / 4	3 / 4	5 / 5	2 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$5M	$4M	$5M	$5M	$5M	$5M
Low	$5M	$4M	$5M	$5M	$5M	$5M
High	$5M	$4M	$5M	$5M	$5M	$5M
EBITDA Avg	$-5M	$-4M	$-5M	$-5M	$-5M	$-5M
Low	$-5M	$-4M	$-5M	$-5M	$-5M	$-5M
High	$-5M	$-4M	$-5M	$-5M	$-5M	$-5M
EBIT Avg	$-5M	$-4M	$-5M	$-5M	$-5M	$-5M
Low	$-5M	$-4M	$-5M	$-5M	$-5M	$-5M
High	$-5M	$-4M	$-5M	$-5M	$-5M	$-5M
Net Income Avg	$-29M	$-34M	$-35M	$-30M	$-35M	$-36M
Low	$-30M	$-39M	$-35M	$-30M	$-35M	$-36M
High	$-27M	$-28M	$-35M	$-30M	$-35M	$-36M
EPS Avg	$-0.22	$-0.26	$-0.27	$-0.23	$-0.27	$-0.27
Low	$-0.23	$-0.30	$-0.27	$-0.23	$-0.27	$-0.27
High	$-0.21	$-0.22	$-0.27	$-0.23	$-0.27	$-0.27
Analysts (Rev / EPS)	2 / 1	3 / 3	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Feb 26, 2026Barclays

C4 Therapeutics (CCCC) PT Raised to $7 at Barclays

Target:$7.00

+149.6%from $2.81

Dec 17, 2025Barclays

C4 Therapeutics price target lowered to $5 from $10 at Barclays

Target:$5.00

+121.2%from $2.26

Sep 23, 2025Wells Fargo

C4 Therapeutics price target raised to $10 from $5 at Wells Fargo

Target:$10.00

+257.1%from $2.80

Sep 22, 2025Barclays

C4 Therapeutics price target raised to $10 from $8 at Barclays

Target:$10.00

+216.5%from $3.16

Sep 16, 2025Barclays

C4 Therapeutics initiated with an Overweight at Barclays

Target:$8.00

+134.6%from $3.41

Sep 15, 2025Stephens

C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens

Target:$6.00

+68.1%from $3.57

Dec 19, 2024Wells Fargo

C4 Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

Target:$12.00

+178.4%from $4.31

Sep 19, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on C4 Therapeutics (CCCC)

Target:$20.00

+191.1%from $6.87

Jan 3, 2023Wells Fargo

Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Lowers Price Target to $9

Target:$9.00

+42.6%from $6.31

Apr 28, 2022Credit Suisse

Credit Suisse Initiates Coverage On C4 Therapeutics with Underperform Rating, Announces Price Target of $10

Target:$10.00

+13.0%from $8.85

Apr 11, 2022Bank of America Securities

C4 Therapeutics (CCCC) Stock: $15 Price Target From BofA

Target:$15.00

+87.3%from $8.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance